BTKi clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Sorry, not yet accepting patients
This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).
Orange, California
Our lead scientists for BTKi research studies include Catherine Coombs.
Last updated: